FILING FEE TABLE
Published on May 23, 2025
Exhibit 107
CALCULATION OF FILING FEE TABLE
Form S-8
(Form Type)
Apimeds Pharmaceuticals US, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1 - Newly Registered Securities
| Security Type | Security Class Title |
Fee Calculation Rule |
Amount Registered |
Proposed Maximum Offering Price Per Share |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee |
|||||||||||||||||
| Equity | Common Stock, par value $0.01 per share | Other(1) | 1,538,462 | (2) | $ | 1.72 | (1) | $ | 2,646,154.64 | 0.00015310 | $ | 405.13 | ||||||||||||
| Total Offering Amounts | $ | 2,646,154.64 | $ | 405.13 | ||||||||||||||||||||
| Total Fee Offsets | $ | – | ||||||||||||||||||||||
| Net Fee Due | $ | 405.13 | ||||||||||||||||||||||
| (1) | Estimated in accordance with Rule 457(c) and Rule 457(h) under the Securities Act, based on the average of the high and low prices of the Registrant’s Class A common stock on The New York Stock Exchange American on May 19, 2025, which date is within five business days prior to filing this registration statement. |
| (2) | Represents shares of common stock that is authorized for issuance under the Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan (the “Plan”). Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this registration statement also includes an indeterminate number of additional shares of common stock that may become issuable pursuant to the anti-dilution provisions of the Plan. |